Frontlight ResearchEarly access
Not yet recruitingPhase 1
Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers
Key facts
- Who runs it
- Korea United Pharm. Inc.
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 60 people, planned
- Started
- Jul 2026
- Planned end
- Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- UI059
- UIC202201
- Record updated
- 27 July 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Healthy adult volunteers aged 19 years or older at the time of screening
- Weight and Body Mass Index (BMI) at screening as follows:; Body weight: ≥50.0kg for males, ≥45.0kg for females; BMI: ≥18.0mg/m2 and ≤ 30.0kg/m2
- Subjects who do not have congenital or chronic diseases requiring treatment and have no pathological symptoms or findings based on medical examination
- Subjects judged suitable for the clinical trial based on laboratory tests, vital signs, physical examination, and 12-lead ECG conducted at screening
- Subjects who test negative for H.pylori antibody at screening
- Subjects who voluntarily decide to participate and provide written informed consent after being fully informed of and understanding the details of this clinical trial and the subject compliance requirements
Who cannot take part
- History of gastrointestinal diseases (e.g., Crohn's disease, ulcers, acute or chronic pancreatitis) or gastrointestinal surgery (excluding simple appendectomy, hernia repair, or dental procedures) that may affect the absorption of the investigational product
- History of clinically significant hypersensitivity (e.g., anaphylaxis or angioedema) to the investigational product ingredients, excipients, or other drugs (e.g., aspirin, penicillin-type antibiotics, macrolide antibiotics, etc.)
- Abnormal diet or consumption of food that may affect the absorption, distribution, metabolism, and excretion (ADME) of the investigational product
- Use of any prescription drugs or herbal medicines within 2 weeks, or any over-the-counter (OTC) drugs or health functional foods within 10 days before the first dose (unless deemed by the investigator not to affect the PK of the investigational product)
- Use of drugs that induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month before the first dose
- Participation and dosing in another clinical trial within 6 months before the first dose
- Whole blood donation within 2 months, component donation within 1 month, or blood transfusion within 1 month before the first dose; or inability to refrain from donation during the study
- Consistent alcohol consumption exceeding 21 units/week (1 unit = 10g of pure alcohol) within 6 months before the first dose, or inability to abstain from alcohol during the study
- Smokers who averaged > 10 cigarettes/day within 3 months before the first dose, or inability to quit smoking from 48 hours before the first dose until the last PK blood collection
- Current or past history of clinically significant liver, kidney, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal diseases
- History of drug abuse or a positive response to drugs of abuse in the urine drug screen
- Clinically significant findings on 12-lead ECG at screening, including:; QTc>450ms(males) or >470ms(females); PR intervals>200ms; QRS duration>120ms
- Clinically significant laboratory results at screening, including:; Liver function (AST, ALT, ALP, γ-GT, and total bilirubin) exceeding 2 times the upper limit of normal (ULN); Serum creatinine outside the reference range, or eGFR calculated by the CKD-EPI formula < 60 mL/min/1.73m2
- Pregnant (positive Urine-HCG test) or breastfeeding women
- Vital signs measured in a sitting position after at least 3 minutes of rest at screening:; Systolic Blood Pressure ≤ 90 mmHg or ≥ 150 mmHg; Diastolic Blood Pressure ≤ 60 mmHg or ≥ 100 mmHg; Pulse Rate ≤ 40 bpm or ≥ 100 bpm
- Consumption of food containing grapefruit within 72 hours before the first dose, or inability to abstain during the study
- Consumption of food containing caffeine (coffee, tea, soda, etc.) from 48 hours before each first dose until the last PK blood collection, or inability to abstain
- Strenuous exercise exceeding normal daily activities within 72 hours before the first dose, or inability to refrain from such exercise
- Subjects (or their partners) planning pregnancy, or those not using medically accepted methods of contraception (e.g., hormonal contraceptives, IUD, sterilization, barrier methods) from the time of consent until 2 weeks after the last dose
- Any other reason the investigator deems the subject unsuitable for participation in the clinical trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers
The 2 groups in the trial
- UI059Treatment being tested
- UIC202201Existing treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Open-label, Multiple-dose, Crossover Phase 1 Clinical Trial to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics Characteristics After Oral Administration of UI059 and UIC202201 in Healthy Adult Volunteers
- Record updated
- 27 July 2026